Background
==========

Cancer is the leading cause of mortality in the developed world and the second leading cause in the developing world \[[@B1]\]. However, systematic data collection in cancer epidemiology over the last 30 years has facilitated the assessment and control of the disease on a global level \[[@B2]-[@B4]\]. More recently, cancer reporting and monitoring projects, such as the GLOBOCAN 2008, have provided both region- and country-specific estimates of the burden of cancer \[[@B5]\]. Where country-specific data were not readily available, these projects would frequently estimate national incidence and mortality rates using incomplete or indirect evidence. Given the lack of complete data for Serbia, the estimates of incidence have been so far based on local cancer registries and extrapolated to the nation's population \[[@B5]\].

The first cancer registries in Serbia were formed in 1970, but became obligatory practice after a change of legal acts in 1986 \[[@B6]\]. Since their formation, information was collected separately by the two cancer registries of Serbia: the Cancer Registry of Central Serbia (CRCS) \[[@B6]\] and the Cancer Registry of Vojvodina (CRV) \[unpublished data -- Miladinov-Mikov\]. In the period from 1986 to 1998, quality of data collection from these two registries was rather poor, but, in 1998 they both became members of the International Agency for Research on Cancer and a new methodology has been applied which substantially improved data quality \[[@B6]\]. Although together these two registries monitor the whole Serbian population (excluding Kosovo and Metohija), they have never published cancer estimates on a national level. Consequently, epidemiological studies presented in the literature either relied on one of the registries, were focused on specific cancer sites, referred to estimates from earlier periods or only reported data for smaller time intervals \[[@B7]-[@B9]\].

The aim of this work is to present nation-wide Serbian cancer incidence and mortality rates using population-based data and to analyse them with respect to the global and European cancer incidence and mortality rates. Additionally, future predictions until the year 2014 on Serbian cancer incidence and mortality rates are also provided. According to the authors' knowledge, this is the first time that such nation-wide population-based cancer data are presented for Serbia. This study is expected to enable the evaluation of cancer burden on the society and help decision makers in planning oncological preventive and curative health care.

Methods
=======

Data sources
------------

Local incidence and mortality data were extracted from the CRV and the CRCS, for the period between 1999 and 2009 \[unpublished data - Miladinov-Mikov, 6\]. Information on incidence and mortality were provided by the registries in age-stratified format in five-year age groups. Validity of the collected data was assessed through the percentage of microscopically (histologically) verified cancers (MV%) and the percentage of cancers certified only after death (DCO%) \[[@B10]\]; completeness was assessed through the mortality/incidence ratio (M/I) \[[@B11]\] (Table [1](#T1){ref-type="table"}). Malignant tumours were coded according to the Tenth Revision of International Classification of Diseases (codes C00-C96) \[[@B12]\]. Demographical data were collected from the census in 2002 and estimates of the Statistical Office of the Republic of Serbia, for all other years of the study period \[[@B13]\].

###### 

Data quality indicators for cancer registry of central Serbia and cancer registry of Vojvodina (1999--2009)

                        **Cancer Registry of Central Serbia**   **Cancer Registry of Vojvodina**                                 
  -------------------- --------------------------------------- ---------------------------------- --------- ---------- --------- ---------
  **Year of report**                  **DCO%**                              **MV%**                **M/I**   **DCO%**   **MV%**   **M/I**
  1999                                  15.4                                  68.3                  62.7       8.0       52.5      66.5
  2000                                  12.3                                  69.8                  57.2       N/A        N/A      69.4
  2001                                   2.3                                  N/A                   54.4       N/A        N/A      60.1
  2002                                   3.1                                  92.6                  54.7       N/A        N/A      61.8
  2003                                   5.7                                  91.4                  56.3       N/A        N/A      62.9
  2004                                   5.5                                  88.4                  55.4       N/A        N/A      60.0
  2005                                   5.5                                  87.2                  57.5       N/A        N/A      59.1
  2006                                   2.9                                  86.8                  57.4       N/A        N/A      58.5
  2007                                   5.3                                  84.0                  56.0       N/A        N/A      61.0
  2008                                   5.4                                  87.1                  58.1       4.5       84.6      57.0
  2009                                   N/A                                  N/A                   56.4       N/A        N/A      57.5

Legend: DCO% - percentage of cancers certified only after death, MV% -- percentage of microscopically verified cancers, M/I mortality/incidence ratio, N/A -- data not available.

In order to standardise the incidence and mortality rates to the world population (age-standardised rates on world population - ASR-W), the following procedure was applied for the ten most common cancer sites in each year. Firstly, we aggregated all new cases/deaths from the two registries per age group. Secondly, we divided these with the age-stratified population estimates for every year, thus calculating the age-specific incidence and mortality rates. Finally, direct standardisation with the world population was performed as defined by Segi et al. \[[@B14]\] and incidence and mortality ASR-Ws were obtained for the whole of Serbia.

Predictions and trends
----------------------

Next to descriptive information on cancer epidemiology, we aimed to provide predictions of cancer incidence and mortality. Since the quality of registration of new cases has been gradually improving through time, as also shown in Table [1](#T1){ref-type="table"}, incidence rates reported in the earlier years (1999--2000) might be less useful for explaining the present and predicting future rates. For this reason, we utilized a prediction method which selectively chooses the most informative sample period, in order to predict incidence/mortality ASR-Ws for the years between 2010 and 2014 \[[@B15]\]. In particular, we used two different regression models: (i) one assuming a linear, age-specific change of incidence/mortality rate over time and (ii) one assuming a linear, age-specific relation between time and the logarithm of incidence/mortality ASR-Ws \[[@B15]\]. These models were used to predict the incidence/mortality rate for a target year, decided to be the latest year of the study period (2009). The former model focuses on the absolute change of incidence or mortality rate while the latter focuses on the proportional change of the rate. Hence, interpretation of the regression parameters should be done cautiously for each model.

In order to identify the most informative sample period for this prediction, we applied both models using information on incidence/mortality from the last four years before 2009 (i.e.2005:2008) and gradually added previous years one by one, up until 2001. This procedure resulted in 2×5 prediction models for age-specific incidence and mortality accordingly. The choice of the appropriate model was then based on the calculated standardized incidence and mortality ratios of the recorded versus the predicted number of total cancer cases or deaths for the target year (2009). The implicit assumption in this method is that the model that makes the best prediction for the most recent available year will also make the best prediction for the future years. After the best fitting model was chosen, predictions for the years 2010--2014 were made. The same model was also used for the estimation of the trend of increase or decrease in the incidence/mortality ASR-Ws through time. All computation within the analysis was conducted using the statistical software R (v.2.13.2) \[[@B16]\].

Comparison with the GLOBOCAN 2008 data
--------------------------------------

Contrasting the incidence and mortality of cancer in Serbia with that in other countries and regions in Europe, as well as worldwide, can establish the relative burden of cancer in Serbia. For that reason we compared the incidence and mortality ASR-Ws from the GLOBOCAN 2008 project \[[@B5]\] with the corresponding rates from Serbia in 2008. Site-specific cancer incidence and mortality ASR-Ws were extracted from the Serbian cancer registries and from GLOBOCAN 2008 for the European countries with the highest and lowest incidence/mortality, all European regions (Southern, Central-eastern, Western and Northern), and the world in total. It should be noted that according to the regional division in GLOBOCAN 2008, Serbia belonged to the countries of Southern Europe \[[@B17]\].

Results
=======

Table [2](#T2){ref-type="table"} presents the number of new cases and the incidence rates for the ten most common cancer sites as well as for all cancer sites combined from 1999 to 2009. In 1999 there were 26,121 incident cancer cases in Serbia (ASR-W: 209.9/100,000, ASR-W in men: 228.9/100,000, ASR-W in women: 197.5/100,000), while this increased to 36,308 newly diagnosed with cancer in 2009 (ASR-W: 277.2/100,000, ASR-W in men: 307.2/100,000, ASR-W in women: 256.4/100,000). For men, lung cancer had the highest incidence rate varying from ASR-W 55.5/100,000 in 1999 to ASR-W 70.8/100,000 in 2009. This was followed by the incidence of colorectal (ASR-W 1999--2009: 27.5/100,000-39.9/100,000), prostate (ASR-W 1999--2009: 12.2/100,000-29.5/100,000) and bladder cancer (ASR-W 1999--2009: 11.7/100,000-16.2/100,000). Among women the most frequently observed cancer in 2009 was breast (ASR-W 1999--2009: 51.5/100,000-70.8/100,000), followed by cervical (ASR-W 1999--2009: 22.7/100,000-25.5/100,000), colorectal (ASR-W 1999--2009: 16.4/100,000-21.1/100,000) and lung cancer (ASR-W 1999--2009: 12.0/100,000-19.4/100,000).

###### 

Cancer incidence and number of new cancer cases in Serbia from 1999 to 2009

                                  **Number of new cancer cases and incidence ASR-Ws/100,000, male population**                                                                                                                 
  ----------------------------- -------------------------------------------------------------------------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  **Cancer site**                                                                                                 **1999**   **2000**   **2001**   **2002**   **2003**   **2004**   **2005**   **2006**   **2007**   **2008**   **2009**
  Lung and bronchus (C34)                                            Cases                                         3,281      3,621      4,135      4,131      4,092      4,139      3,992      4,044      3,795      4,193      4,354
  ASR-W                                                               55.5                                          60.7       69.0       67.6       67.2       67.9       65.4       66.7       61.3       68.0       70.8    
  Colon and rectum (C18-C20)                                         Cases                                         1,690      1,729      1,953      2,130      2,166      2,202      2,240      2,094      2,459      2,698      2,566
  ASR-W                                                               27.5                                          28.1       31.6       33.5       34.2       34.6       35.1       32.8       38.7       41.5       39.9    
  Prostate (C61)                                                     Cases                                          813        973       1,127      1,279      1,333      1,354      1,501      1,662      1,776      1,891      2,193
  ASR-W                                                               12.2                                          14.4       16.3       17.4       18.9       19.1       20.9       22.9       23.9       25.9       29.5    
  Bladder (C67)                                                      Cases                                          733        890        955       1,044       951       1,000      1,009      1,045      1,126      1,044      1,071
  ASR-W                                                               11.7                                          14.4       14.9       16.0       14.8       15.5       15.8       15.7       16.8       15.6       16.2    
  Stomach (C16)                                                      Cases                                          801        837        908        972        857        840        789        747        890        855        729
  ASR-W                                                               13.3                                          13.6       14.8       15.4       13.6       13.1       12.4       11.9       13.9       13.2       11.1    
  Larynx (C32)                                                       Cases                                          604        677        721        709        679        665        618        732        677        661        626
  ASR-W                                                               10.5                                          11.7       12.4       12.1       11.6       11.2       10.6       12.5       11.4       11.2       10.6    
  Brain (C71)                                                        Cases                                          349        378        377        414        465        473        396        423        413        393        396
  ASR-W                                                               7.1                                           8.0        7.9        8.5        9.3        9.9        7.7        8.6        8.0        7.9        7.9     
  Mouth and pharynx (C00-C10)                                        Cases                                          430        532        494        474        468        457        454        473        435        516        493
  ASR-W                                                               7.5                                           9.3        8.6        8.1        8.0        7.7        7.7        7.9        7.3        8.6        8.2     
  Leukemias (C91-C95)                                                Cases                                          302        304        332        339        386        335        348        308        405        309        318
  ASR-W                                                               6.5                                           6.9        7.0        6.9        8.0        6.7        6.8        6.2        7.4        5.8        6.6     
  Pancreas (C25)                                                     Cases                                          326        337        432        435        399        458        434        383        457        476        450
                                                                     ASR-W                                          5.4        5.6        7.0        7.0        6.3        7.5        7.0        6.1        7.4        7.3        7.1
  **All sites (C00-C97)**                                            Cases                                         13,344     15,062     16,128     16,670     16,617     17,049     16,943     17,349     17,801     18,565     19,076
                                                                     ASR-W                                         228.9      255.8      272.8      274.3      276.0      283.2      277.5      284.0      286.3      296.1      307.2
                                 **Number of new cancer cases and incidence ASR-Ws/100,000, female population**                                                                                                                
                                                               **Year of report**                                                                                                                                              
  **Cancer site**                                                                                                 **1999**   **2000**   **2001**   **2002**   **2003**   **2004**   **2005**   **2006**   **2007**   **2008**   **2009**
  Breast (C50)                                                       Cases                                         3,193      3,692      3,807      3,935      3,866      3,625      3,650      3,791      3,865      4,026      4,518
  ASR-W                                                               51.5                                          59.3       60.4       63.0       60.2       56.9       57.1       58.9       59.9       62.0       70.8    
  Cervix uteri (C53)                                                 Cases                                         1,271      1,341      1,376      1,380      1,287      1,236      1,276      1,392      1,183      1,276      1,423
  ASR-W                                                               22.7                                          24.1       25.6       25.1       23.2       22.7       23.3       24.9       21.1       23.0       25.5    
  Colon and rectum (C18-C20)                                         Cases                                         1,203      1,241      1,382      1,492      1,549      1,575      1,591      1,595      1,768      1,642      1,614
  ASR-W                                                               16.4                                          16.8       18.7       19.6       20.3       20.9       20.8       20.9       23.1       21.1       21.1    
  Lung and bronchus (C34)                                            Cases                                          808       1,026      1,114      1,172      1,178      1,288      1,178      1,173      1,152      1,358      1,383
  ASR-W                                                               12.0                                          15.3       16.4       16.9       16.7       18.3       17.0       16.8       16.1       19.5       19.4    
  Corpus uteri (C54)                                                 Cases                                          763        829        767        772        829        827        869        823        844        895        954
  ASR-W                                                               11.7                                          12.4       11.9       11.7       12.0       12.5       12.5       12.2       12.5       13.1       14.1    
  Ovary (C56)                                                        Cases                                          595        641        623        641        606        638        694        602        616        652        626
  ASR-W                                                               9.8                                           10.5       10.0       10.6       9.8        10.4       11.5       9.8        9.8        10.9       10.3    
  Stomach (C16)                                                      Cases                                          404        468        463        502        512        561        493        492        507        482        413
  ASR-W                                                               5.3                                           6.3        6.2        6.5        6.3        7.1        6.6        6.3        6.5        6.1        5.2     
  Brain (C71)                                                        Cases                                          232        288        301        317        315        370        308        310        329        310        330
  ASR-W                                                               4.5                                           5.9        6.0        6.0        6.1        6.9        5.3        5.8        5.9        5.4        6.2     
  Leukaemias (C91-C95)                                               Cases                                          215        213        259        270        263        252        253        225        294        186        205
  ASR-W                                                               4.1                                           3.9        4.7        5.1        5.1        4.6        4.6        4.0        4.9        3.2        3.7     
  Pancreas (C25)                                                     Cases                                          265        270        289        331        337        349        412        286        347        328        357
  ASR-W                                                               3.5                                           3.5        3.7        4.3        4.2        4.3        5.0        3.7        4.1        3.9        4.4     
  **All sites (C00-C97)**                                            Cases                                         12,777     14,655     14,943     15,427     15,484     15,786     15,684     15,817     15,923     16,666     17,232
                                                                     ASR-W                                                    197.5      225.9      230.6      235.7      233.6      236.9      233.8      235.1      232.3      244.3

Legend: ASR-W -- age-standardised rate on world population. Codes in brackets next to presented cancer sites are in accordance with the Tenth Revision of International Classification of Diseases (codes C00-C96).

Table [3](#T3){ref-type="table"} presents the mortality rates and the number of fatal cases, from 1999 to 2009, for the ten most common cancer sites and for all sites combined. In Serbia 1999, 17,375 people died from cancer (ASR-W: 129.6/100,000, ASR-W in men: 163.2/100,000, ASR-W in women: 102.7/100,000) while the number inclined to 21,069 cancer deaths in 2009 (ASR-W: 143.8/100,000, ASR-W in men: 181.1/100,000, ASR-W in women: 113.8/100,000). The highest mortality rate for men was observed for lung cancer (ASR-W 1999--2009: 48.5/100,000-58.0/100,000) followed by colorectal (ASR-W 1999--2009: 17.8/100,000-21.9/100,000), stomach (ASR-W 1999--2009: 12/100,000-10.8/100,000) and prostate cancer (ASR-W 1999--2009: 9.1/100,000-11.5/100,000). In women, the highest mortality rates were attributed to breast (ASR-W 1999--2009: 22.3/100,000-22.5/100,000), lung (ASR-W 1999--2009: 10.0--16.7/100,000), colorectal (ASR-W 1999--2009: 10.4/100,000-12.0/100,000) and cervical cancer (ASR-W 1999--2009: 7.4/100,000-7.2/100,000).

###### 

Cancer mortality and number of cancer deaths in Serbia from 1999 to 2009

                                 **Number of cancer deaths and mortality ASR-Ws/100,000, male population**                                                                                                                 
  ---------------------------- ----------------------------------------------------------------------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----------
  **Cancer site**                                                                                             **1999**   **2000**   **2001**   **2002**   **2003**   **2004**   **2005**   **2006**   **2007**   **2008**   **2009**
  Lung and bronchus (C34)                                         Deaths                                       2,915      3,054      3,107      3,199      3,212      3,350      3,454      3,647      3,678      3,717      3,676
  ASR-W                                                            48.5                                         50.4       50.8       51.6       51.9       54.1       55.4       58.2       58.0       59.1       58.0    
  Colon and rectum (C18-C20)                                      Deaths                                       1,124      1,158      1,167      1,244      1,205      1,309      1,383      1,338      1,367      1,438      1,537
  ASR-W                                                            17.8                                         18.3       18.1       18.8       18.3       19.7       20.8       19.9       19.6       20.8       21.9    
  Stomach (C16)                                                   Deaths                                        742        769        767        788        753        787        730        657        713        691        735
  ASR-W                                                            12.0                                         12.3       12.2       12.0       11.6       11.9       11.1       10.1       10.7       10.4       10.8    
  Prostate (C61)                                                  Deaths                                        610        535        605        680        760        759        819        881        948        927        977
  ASR-W                                                             9.1                                         7.9        8.6        8.9        10.3       10.1       10.5       11.1       11.8       11.5       11.5    
  Pancreas (C25)                                                  Deaths                                        403        391        417        435        442        459        502        488        491        534        520
  ASR-W                                                             6.6                                         6.3        6.6        6.7        6.9        7.2        7.9        7.6        7.4        7.9        7.9     
  Liver (C22)                                                     Deaths                                        383        419        389        352        390        374        373        412        468        420        438
  ASR-W                                                             6.1                                         6.6        6.1        5.4        6.0        5.6        5.7        6.1        6.9        6.3        6.4     
  Larynx (C32)                                                    Deaths                                        403        409        384        357        426        366        358        382        366        356        391
  ASR-W                                                             6.7                                         6.9        6.4        5.9        6.9        5.9        5.6        6.2        5.8        5.6        6.2     
  Brain (C71)                                                     Deaths                                        292        295        289        271        327        306        321        338        379        322        331
  ASR-W                                                             5.8                                         5.8        5.5        5.0        6.0        5.4        6.0        6.4        6.6        5.9        5.7     
  Bladder (C67)                                                   Deaths                                        371        344        386        453        417        426        403        495        472        407        453
  ASR-W                                                             5.7                                         5.3        5.8        6.5        6.0        6.1        5.6        7.0        6.4        5.5        6.0     
  Leukaemias (C91-C95)                                            Deaths                                        238        228        252        230        249        231        279        281        342        293        299
                                                                   ASR-W                                        4.3        4.1        4.5        4.0        4.4        4.0        4.9        4.6        5.7        4.6        4.9
  **All sites (C00-C97)**                                         Deaths                                       9,870      10,179     10,175     10,635     10,690     10,982     11,169     11,495     11,736     11,775     11,999
                                                                   ASR-W                                       163.2      166.3      164.7      166.6      169.3      172.0      174.2      177.3      179.0      179.6      181.1
                                **Number of cancer deaths and mortality ASR-Ws/100,000, female population**                                                                                                                
                                                            **Year of report**                                                                                                                                             
  **Cancer site**                                                                                             **1999**   **2000**   **2001**   **2002**   **2003**   **2004**   **2005**   **2006**   **2007**   **2008**   **2009**
  Breast (C50)                                                    Deaths                                       1,497                 1,511      1,515      1,464      1,608      1,628      1,676      1,643      1,623      1,653
  ASR-W                                                            22.3                                         22.6       21.9       20.8       23.0       23.3       23.3       22.2       21.2       22.7       22.5         
  Lung and bronchus (C34)                                         Deaths                                        712        790        810        857        911        957        980       1,089      1,096      1,107      1,265
  ASR-W                                                            10.0                                         11.1       11.2       11.8       12.4       13.0       13.1       14.9       14.5       14.9       16.7         
  Colon and rectum (C18-C20)                                      Deaths                                        813        845        841        905        937        957       1,070      1,036       990       1,065      1,073
  ASR-W                                                            10.4                                         10.4       10.3       10.5       11.3       11.5       12.5       12.1       11.0       12.3       12.0         
  Cervix uteri (C53)                                              Deaths                                        486        471        490        543        501        497        519        523        523        536        490
  ASR-W                                                             7.4                                         7.4        7.7        8.3        7.4        7.6        7.9        8.0        7.7        8.2        7.2          
  Stomach (C16)                                                   Deaths                                        400        436        407        397        424        468        452        393        412        393        417
  ASR-W                                                             5.0                                         5.6        5.2        4.8        4.9        5.7        5.5        4.7        4.9        4.6        5.3          
  Ovary (C56)                                                     Deaths                                        335        311        363        331        341        348        374        402        390        388        424
  ASR-W                                                             4.9                                         4.7        5.2        4.8        4.9        5.0        5.1        5.8        5.4        5.5        5.9          
  Pancreas (C25)                                                  Deaths                                        306        318        323        349        372        349        448        366        475        435        447
  ASR-W                                                             3.9                                         3.9        3.9        4.2        4.5        4.0        5.1        4.3        5.2        4.8        4.8          
  Brain (C71)                                                     Deaths                                        192        206        214        232        227        231        233        281        279        255        292
  ASR-W                                                             3.2                                         3.3        3.6        3.9        3.6        3.9        3.6        4.2        4.3        4.0        4.4          
  Liver (C22)                                                     Deaths                                        256        293        275        242        251        278        266        304        312        260        291
  ASR-W                                                             3.1                                         3.7        3.3        2.9        3.1        3.1        3.1        3.4        3.6        2.9        3.3          
  Leukaemias (C91-C95)                                            Deaths                                        195        175        196        186        187        176        175        233        223        215        224
  ASR-W                                                             3.1                                         2.6        3.0        2.8        2.7        2.5        2.6        3.5        2.9        2.9        2.9          
  **All sites (C00-C97)**                                         Deaths                                       7,505      7,694      7,742      7,911      8,169      8,380      8,572      8,722      8,681      8,787      9,070
                                                                   ASR-W                                       102.7      104.0      103.6      103.7      106.2      108.0      108.8      110.4      108.6      112.7      113.8

Legend: ASR-W -- age-standardised rate on world population. Codes in brackets next to presented cancer sites are in accordance with the Tenth Revision of International Classification of Diseases (codes C00-C96).

Predictions and trends
----------------------

Figure [1](#F1){ref-type="fig"} presents the overall ASR-W cancer incidence and mortality for men and women from 1999 to 2009 (solid lines). In addition, predictions until 2014 for overall cancer incidence and mortality are presented (dotted lines). An increasing time trend can be observed for cancer incidence and mortality in both genders. In particular, linear regressions of time on the log of mortality and incidence revealed that, in men, incidence and mortality ASR-Ws increased by 2.5% (*P* = 0.004) and 1% (*P* \< 0.001) per year, respectively. For women, the incidence ASR-W was estimated to be increasing by 2.22% per year, although this increase was not statistically significant (*P* = 0.067). The cancer mortality rate for women was found to be significantly increasing by 1% (p \< 0.001) per year.

![**Overall cancer incidence and mortality in Serbia - trends (1999--2009) and predictions (2010--2014).** Legend: Red bold line -- incidence, men. Red regular line -- incidence, women. Black bold line -- mortality, men. Black regular line, mortality, women. All dotted lines continuous to these are depicting predictions.](1471-2407-13-18-1){#F1}

Figure [2](#F2){ref-type="fig"} presents the time trend for cancer incidence and mortality rates for the four main cancer sites in men and women from 1999 to 2009 as well as incidence and mortality rates' predictions from 2010 to 2014. Linear regressions of time on incidence revealed that in both genders all cancer sites analysed showed a positive trend over time. In men, the incidence of prostate cancer has been increasing with 1.948/100,000 (*P* \< 0.001) per year, faster than any other cancer analysed in the male population. A significant increase was also observed for the incidence ASR-W of colorectal cancer with approximately 1.084/100,000 (*P* = 0.013). In women, breast cancer showed the highest increase in incidence with an additional ASR-W of 3.065/100,000 (*P* = 0.034) every year. In the analysis of mortality ASR-Ws, colorectal cancer in men and lung cancer in women were estimated to have the most significant increase over time: 0.42/100,000 (*P* = 0.036) and 0.626/100,000 (*P* \< 0.001) per year, respectively.

![**Trends in incidence and mortality from the four most common cancers in Serbia (1999--2009) and predictions (2010--2014).** Legend: Blue line -- lung cancer. Orange line -- colorectal cancer. Turquoise line -- prostate cancer. Green line -- bladder cancer. Dark red line -- stomach cancer. Pink line -- breast cancer. Light green line -- cervical cancer.](1471-2407-13-18-2){#F2}

Comparison with the GLOBOCAN 2008 data
--------------------------------------

Figure [3](#F3){ref-type="fig"}A presents the men's incidence ASR-Ws in Serbia for 2008 against European and worldwide estimates that were extracted from GLOBOCAN 2008. The incidence of lung (ASR-W: 68.0/100,000) and colorectal (ASR-W:41.5/100,000) cancer in Serbia was higher than the average incidence in any European region or in the world. Conversely, prostate cancer in Serbia had a lower incidence rate (ASR-W: 25.9/100,000) than the average in all European regions or the world (ASR-W: 27.9/100,000 -- 93.1/100,000). Finally, the overall cancer incidence in the Serbian male population (ASR-W: 296.1/100,000) was closest to the average incidence in Southern Europe (ASR-W: 289.1/100,000). The mortality rates for lung (ASR-W: 59.1/100,000) and colorectal cancer (ASR-W: 20.8/100,000) for men in Serbia were also above the average European and world mortality rates (Figure [3](#F3){ref-type="fig"}B). Similarly, the overall mortality rate (ASR-W: 179.6/100,000) was higher than world and European averages and comparable to Hungary, the country with the highest cancer mortality in Europe (ASR-W: 229.5/100,000). On the contrary, the mortality rate for prostate cancer (ASR-W: 11.5/100,000) in Serbia was similar to the European average.

![**(A) Comparison of Serbian incidence ASR-Ws with the GLOBOCAN 2008 estimates -- men; (B), Comparison of Serbian mortality ASR-Ws with the GLOBOCAN 2008 estimates -- men.** N Europe -- Northern Europe, S Europe -- Southern Europe, W Europe -- Western Europe, CE Europe -- Central Eastern Europe. \* - Eureopan country with the lowest incidence/mortality ASR-W. \*\* - European country with the highest incidence/mortality ASR-W.](1471-2407-13-18-3){#F3}

The women's cancer incidence in Serbia, Europe and the world, for 2008, are presented in Figure [4](#F4){ref-type="fig"}A. The incidence of cervical cancer in Serbia (ASR-W: 23.0/100,000) was observed to be higher than all average European/global estimates and almost equal to the highest European rate found in Romania (ASR-W: 23.9/100,000). The incidence of breast (ASR-W: 62.0/100,000), colorectal (ASR-W: 21.1/100,000) lung (ASR-W: 19.5/100,000) and all cancers combined (ASR-W: 244.3/100,000) in Serbia was close to the average value of the comparators. Finally, comparison of women's cancer mortality indicated that breast cancer mortality in Serbia (ASR-W: 22.7/100,000) was the highest in Europe in 2008 (Figure [4](#F4){ref-type="fig"}B). Additionally, mortality of colorectal (ASR-W: 12.3/100,000) cervical cancer (ASR-W: 8.2/100,000) and overall cancer (ASR-W: 112.7/100,000) in Serbian women was above the average regional and global estimates though below the countries with the highest European rates.

![**(A) Comparison of Serbian incidence ASR-Ws with the GLOBOCAN 2008 estimates --women; (B), Comparison of Serbian mortality ASR-Ws with the GLOBOCAN 2008 estimates -- women.**N Europe -- Northern Europe, S Europe -- Southern Europe, W Europe -- Western Europe, CE Europe -- Central Eastern Europe. B&H -- Bosnia and Herzegovina. \* - Eureopan country with the lowest incidence/mortality ASR-W. \*\* - European country with the highest incidence/mortality ASR-W.](1471-2407-13-18-4){#F4}

Discussion
==========

This study presents, for the first time, nation-wide data on incidence and mortality from cancer in Serbia over the last decade and a comparison with European and world figures. The main findings of this study are the significant increase of overall cancer incidence and mortality within the observed period in Serbia as well as the alarmingly high mortality rates of Serbia compared to the rest of Europe.

Per-site comparison of incidence and mortality with respective European estimates identified four cancer sites that should attract serious attention. In 2008, Serbia was the country with the highest mortality due to breast cancer in Europe, while incidence of cervical cancer was only slightly lower than the highest European rate, recorded in Romania. In the male population of Serbia, incidence and mortality rates of lung and colorectal cancers, although not the highest in Europe, were well above average estimates. Oppositely, the only rate within the comparison found to be lower in Serbia was prostate cancer incidence.

The comparatively high levels of cancer incidence observed can, to a large extent, be attributed to the prevalence of cancer risk factors. For instance, tobacco and alcohol consumption have a well-established association with increased risk of several cancer types \[[@B18],[@B19]\]. These health hazards are reported as excessively present in contemporary Serbia, where half of all men and one third of all women actively smoke \[[@B20]\], while 40% of the total population consumes alcohol occasionally or on everyday basis \[[@B21]\]. Moreover, risk factors for cancer such as lack of physical activity and obesity \[[@B22],[@B23]\] are also largely present among the Serbian population. In particular, in a representative sample of Serbian adults only a 10% was found to be engaged to a daily physical activity and about 55% were overweight \[[@B24]\]. Although some action in controlling risk factors in the population have been introduced by the Serbian health care system, as for example the creation of a legislation framework for tobacco control \[[@B20]\], more effort towards risk-factor reductions is needed. Finally, the country is still in an economic transition which influences the people's lifestyle and, as reported, might have negative effect on trends in cancer epidemiology \[[@B25]\].

In addition to this high level of incidence in comparison to the rest of Europe, Serbia is confronted with an even higher relative mortality rate. Since it is known that cancer survival declines with the increase of mortality/incidence ratio \[[@B26]\], cancer survival in Serbia might be poorer than in other European countries/regions. Furthermore, this could also be a sign of delayed cancer diagnosis, which is the main differentiating factor for survival in several cancer types \[[@B27]\]. Lack of screening methods that can facilitate early cancer detection is one of the reasons behind this high relative mortality. Particularly, the opportunistic screening methods available usually do not target the general population, or at least the population at risk. For example, planning of an organized, cytology-based screening for cervical cancer started more than a decade ago \[[@B28]\], yet it still remains on the level of an opportunistic program with high coverage in younger and quite low coverage in elderly women \[[@B29]\]. The implementation of screening programs such as cytology-based screening or mammography could facilitate early detection in cervical and breast cancer respectively and thereby positively impact survival \[[@B30],[@B31]\]. Additionally, improvement in survival after colorectal cancer would be possible through the application of a fecal occult blood test \[[@B32]\]. Hence, prevention and early diagnosis could improve survival and decrease cancer mortality in Serbia.

The trend of incidence of breast cancer in Serbia largely follows the increasing incidence pattern that is currently observed in the rest of the European countries \[[@B33]\]. One reason behind such increase in Serbia is the recent implementation of opportunistic mammography screening \[[@B34]\]. However, breast cancer mortality in Serbia has so far remained constant in contrast to the decreasing trend observed in breast cancer mortality throughout Europe and especially in the northern and western European countries \[[@B35]\]. Since the decrease of breast cancer mortality in Europe has been mainly attributed to advancements in therapy \[[@B35]\], it could be argued that the absence of similar trend in Serbia is caused by delays in the adoption of new treatment alternatives. In men, although prostate cancer incidence in Serbia still remains generally low compared to the rest of Europe, the steep increase of the incidence might be attributed to both lifestyle changes as well as to more widespread use of prostate specific antigen (PSA) testing \[[@B36]\].

Prior epidemiological studies that were conducted for Serbia mainly focused on specific cancer sites. Most of them pinpointed the increasing cancer incidence and mortality \[[@B7]-[@B9],[@B28],[@B37]\]. More specifically, high cervical cancer incidence relative to other European countries was noted already at the beginning of the last decade \[[@B28],[@B37]\], the insufficiency of screening utilization was identified as the main cause for this excess in incidence. Increasing trends in breast and lung cancer in Vojvodina were observed in the periods from 1987 until 2001 and from 1996 until 2005, respectively \[[@B7],[@B8]\]. Finally, one study estimated the burden of several cancers in Serbia relative to that in Europe for the year 2000 \[[@B9]\]. This study relied on local data from both cancer registries of Serbia and identified the considerably higher burden of the disease in Serbia.

Our study is also confronted with a number of limitations. A major limitation is the absence of nation-wide cancer survival and prevalence data. Survival and prevalence estimates are typically included in nation-wide cancer epidemiology studies, yet this information is not available for Serbia. Such estimates would require frequent follow up on patient cohorts, something that, due to financial constraints, would be nearly impossible in Serbia nowadays. Moreover, comparisons across Europe were done only with the countries that had the highest and lowest incidence and mortality rates, in order to gain insight on the magnitude of a certain ASR-W in Europe. Additionally, the lack of age-specific cancer incidence and mortality estimates from GLOBOCAN 2008 did not permit a formal statistical comparison between the ASR-Ws of Serbia and the other European regions and countries. In a more detailed analysis, presentation of age-specific cancer evidence from a larger number of European countries could give more precisely the relative position of Serbia with respect to its cancer epidemiology.

Conclusion
==========

Incidence and mortality of all cancer sites combined in Serbia have shown a steady increase in the first decade of their systematic reporting. Overall mortality rates in both genders appear markedly high relative to European/global estimates. Site-specific comparison revealed alarmingly high rates for four cancer locations: breast and cervical cancer in women and lung and colorectal cancer in men. In light of these findings, we believe that better control of known risk factors should lead to positive change in Serbian cancer epidemiology. Furthermore, prevention and early diagnosis, especially of breast and cervical cancers, seem to be the areas where significant improvements still could be made.
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